Total Compensation: $ —
Gerard Le Fur has degrees in both pharmacy and science. He began his career at Laboratoires Pharmuka as Chief of Laboratories and later served as Assistant Director of Research and Development before joining Laboratoires Rhone-Poulenc as Director of Biology. He joined Sanofi in 1986 as Assistant Director of Research and Development, and was named Director of Research and Development in 1995, prior to being named Executive Vice President, Scientific Affairs in June 1999 following the merger with Synthelabo. He was appointed Senior Executive Vice President in December 2002, and reappointed to the same position in June 2004. In August 2004, he was appointed Executive Vice President, Scientific and Medical Affairs. He was appointed Chief Executive Officer as of January 1, 2007.
Total Compensation: $ —
Laurence Debroux is a graduate of HEC (Ecole des Hautes Etudes Commerciales). She began her career with Merrill Lynch in London, and then worked in the Finance Department of the Elf Aquitaine Group from 1993 to 1996. She joined the Sanofi Group as Corporate Treasurer in 1996, and was appointed Head of Financing/Treasury in 1997. From 2000 to 2004, she served as Head of Strategic Planning, before becoming Deputy Chief Financial Officer. She was appointed to her present position in March 2007.
Total Compensation: $ —
Karen Linehan graduated from Georgetown University with bachelor of arts and juris doctorate degrees. Prior to practicing law, Ms. Linehan served on the congressional staff of the Speaker of the U.S. House of Representatives from September 1977 to August 1986. Until December 1990, she was an Associate in a mid-size law firm in New York, New York. In January 1991, she joined Sanofi as Assistant General Counsel of its US subsidiary. In July 1996, Ms. Linehan moved to Paris to work on international matters within the Group and she has held a number of positions within the Legal Department, most recently as Vice President - Deputy Head of Legal Operations. She was appointed to her current position in March 2007.
Total Compensation: $ —
Belen Garijo has a degree in medicine, majoring in clinical pharmacology. Her career in the pharmaceutical industry began at Abbott, where she was Medical Director of the Spanish subsidiary before being appointed Director of International Medical Affairs at Abbott's United States headquarters in Illinois. In 1996, she joined Rhone-Poulenc Rorer in Spain as Head of the Oncology Business Unit. She was subsequently responsible for Aventis' global marketing and medical strategy in Oncology, based in New Jersey, United States. She returned to Spain in 2003 as Managing Director of the Group's Spanish subsidiary. She was appointed to her current position in July 2006. The commercial operations of Germany have reported to Belen Garijo since January 1, 2008.
Total Compensation: $ —
—
Total Compensation: $ —
Christian Mulliez, Vice President, General Manager Administration and Finance of L'Oreal. Chairman of the Board of Directors of Regefi. Director of DG 17 Invest and L'Oreal USA Inc. and The Body Shop International (United Kingdom).
Total Compensation: $ —
—
Total Compensation: $ —
Jean-Marc Bruel, Chairman of Firmenich (Switzerland). Director of L'Institut Curie.
Total Compensation: $ —
Igor Landau, Director of HSBC France and INSEAD. Member of the Supervisory Boards of Allianz AG (Germany) and Adidas-Salomon (Germany).
Total Compensation: $ —
Klaus Pohle, Vice-Chairman of the Supervisory Board, Chairman of the Audit Committee and Member of Nomination and Corporate Governance Committee of Hypo Real Estate Holding AG, Munich (Germany). Director of Coty Inc., New York. Chairman of the Audit Committee of Coty Inc., New York. Member of the Supervisory Board and Chairman of the Audit Committee of DWS Investment GmbH, Frankfurt (Germany).
Total Compensation: $ —
Pierre Chancel, a pharmacist, is a graduate of the Institut de Pharmacie Industrielle in Paris. At Rhone-Poulenc, from 1994 to 1996, he was Marketing Director for Theraplix. From 1997 to 1999, Mr. Chancel served as Business Unit Manager in charge of products in the central nervous system, rheumatology and hormone replacement therapy fields. From 2003, he served as Managing Director of Aventis Operations in the United Kingdom and Ireland. Before being appointed to this position, he was in charge of global strategy development at Aventis, which led to the launch of the new diabetes treatment Lantus(r). He was appointed to his present position in August 2004.
Total Compensation: $ —
Olivier Charmeil is a graduate of HEC (Ecole des Hautes Etudes Commerciales) and of the Institut d'Etudes Politiques in Paris. From 1989 to 1994, he worked in the Mergers & Acquisitions department of Banque de l'Union Europeenne. He joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Syntheeabo in 1999 and Attache to the Chairman, Jean-Francois Dehecq, in 2000, before being appointed as Vice President, Development within the Sanofi-Synthelabo International Operations Directorate, where he was responsible for China and support functions. In 2003, Olivier Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthelabo France, before taking the post of Senior Vice President, Business Management and Support within the Pharmaceutical Operations Directorate. In this role, he piloted the operational integration of Sanofi-Synthelabo and Aventis. He was appointed to his current position in February 2006. Since January 1, 2008, Operations Japan have reported to Olivier Charmeil.
Total Compensation: $ —
Marc Cluzel is a Doctor of Medicine and a Doctor of Science. He began his career in hospital medicine before carrying out research at Johns Hopkins University (Baltimore) and Guy's Hospital (London). In 1991, he joined Sanofi Recherche as a clinical pharmacologist, and was then appointed successively as Senior Project Director in 1993, Vice President, Research Projects Management in 1996 (retaining this position after the 1999 merger with Synthelabo) and Vice President, International Development in 2001 (retaining this position after the 2004 merger with Aventis). Marc Cluzel was appointed to his current position in January 2007.
Total Compensation: $ —
Philippe Fauchet is a graduate of HEC (Ecole des Hautes Etudes Commerciales), and also holds a law degree. After two years with a subsidiary of Renault, Philippe Fauchet joined Roussel Uclaf in 1984, and, held a number of posts in France, Japan and Korea, before becoming Vice President of the Asia-Pacific region for Hoechst Marion Roussel. He joined Sanofi in 1996, and headed up the Eastern Europe region from 1997, before becoming Vice President, Eastern Europe for Sanofi-Synthelabo in 1999. Philippe Fauchet took over as head of Sanofi-Synthelabo's Japanese operations in June 2001. He was appointed to his current position in May 2005. He is also an advisor to the French Foreign Trade Commission.
Total Compensation: $ —
Gregory Irace holds a B.S. in accounting from Albany State University (New York). He began his career at Price Waterhouse in 1980 and received his CPA in 1982. He spent 11 years at Price Waterhouse becoming a Senior Audit Manager in 1988, and a Senior Manager in the Corporate Finance Department in 1989. In 1991 he joined Sterling Winthrop Inc. as Regional Controller and in 1993 he became Director of Financial Planning and Analysis for Sanofi Winthrop L.P. From October 1994 to January 2007, he was Chief Financial Officer of Sanofi's Pharmaceutical Operations in the United States, most recently serving as Senior Vice President, Finance and Administration and Chief Financial Officer of sanofi-aventis US. He was appointed to his present position in February 2007.
Total Compensation: $ —
Michel Labie is a graduate of the Taipei Ecole Normale de Langues (Taiwan), holds a diploma in Chinese from the Institut National des Langues et Civilisations Orientales (INALCO) and a bachelor degree (maitrise) in Chinese Traditional Pharmacopoeia. He began his career with Sanofi in 1981, opening the company's Beijing bureau in China in 1982. In 1995, he moved to France as head of International Professional Relations, before becoming head of Institutional and Professional Relations in 2001. Michel Labie was appointed Vice President, Assistant Director of Communication in June 2006, and took up his current post in November 2006, retaining his responsibilities in the Institutional and Professional Relations Department.
Total Compensation: $ —
Jean-Michel Levy, a graduate of HEC (Ecole des Hautes Etudes Commerciales), joined the Midy Group in 1969. He held various positions in Marketing and Business Development, first at Clin Midy and then at Sanofi. Since 1989, he has worked in the Finance and Strategy Departments in a variety of roles connected with acquisitions and strategy/planning. He was appointed to his current position in January 2007.
Total Compensation: $ —
Heinz-Werner Meier holds a degree in mathematics and a doctorate in business management. He began his career in 1978 working in research and development for Siemens AG in Germany. He then worked as a scientific assistant in the Faculty of Business Management, Organization and Information Technology at Mannheim University. In 1985, he joined the Hoechst Group as Purchasing Director and successively as Finance and Accounting Director at the subsidiary Benckiser-Knapsack GmbH. From 1995 he was Global Group Controller in the Pharmaceuticals Division of Hoechst AG and from 1997 Managing Director of Hoechst Marion Roussel Germany. From January 2000 to May 2002, he was Chairman of Aventis Pharma Germany, and until August 2004 a member of the Board of Aventis and Director of Human Resources. He served as Senior Vice President Pharmaceutical Operations Germany from August 2004 to December 31, 2007. Since October 2006, he has also served as Senior Vice President Corporate Human Resources and retains these responsibilities.
Total Compensation: $ —
Antoine Ortoli is a graduate of the Ecole Superieure de Commerce in Rouen, France, and of INSEAD. He also holds a law degree and an accountancy qualification. He began his career in 1980 as a financial and systems auditor with Arthur Young and Co. In December 1981, he joined the Sanofi Group, where he served in a variety of positions, including Finance Director of the Pharmaceuticals Division and Director of the Latin America region. Following the merger with Synthelabo in 1999, he was named as Vice President, Latin America, and then as Senior Vice President, Asia Middle East in June 2001. In June 2003, he took on the role of Vice President, Intercontinental region at Sanofi-Synthelabo. He was appointed to his present position in January 2005.
Total Compensation: $ —
Philippe Peyre is a graduate of the Ecole Polytechnique, and began his career in management consultancy with Bossard before being appointed as a member of the General Management Committee of Bossard Gemini Consulting. In 1998, he joined Rhone-Poulenc Rorer as Senior Vice President Special Projects, and then served as Head of Integration at Aventis Pharma, and as Company Secretary and Senior Vice President, Business Transformation of Aventis. He was appointed to his present position in August 2004.
Total Compensation: $ —
David J. Williams holds a degree in accounting and management from Scranton University in Pennsylvania. After working four years with Coopers & Lybrand, in January 1978, he joined the U.S. operating unit of Connaught Laboratories, Inc., serving in a variety of financial and marketing positions before being appointed in 1981 Vice President and General Manager of U.S. Operations. In 1988, he was named President and Chief Operating Officer of Connaught Laboratories, Inc., a position he held for a decade. In 1998 he became Chief Executive Officer of Pasteur Merieux Serums et Vaccins. Since January 2003, he has served as Chairman and Chief Executive Officer of sanofi pasteur. In August 2004, he was appointed to his present position.
Total Compensation: $ —
Jean-Rene Fourtou, Chairman and Chief Executive Officer of Vivendi Universal. Chairman of the Supervisory Board of Groupe Canal +. Honorary Chairman of the International Chamber of Commerce. Vice-Chairman of the Supervisory Board of Axa. Member of the Board of Directors of Axa Millesimes SAS. Member of the Supervisory Board of Maroc Telecom. Director of Cap Gemini SA and NBC Universal Inc. (United States), Axa Millesimes SAS and Nestle.
Total Compensation: $ —
Gerard Van Kemmel, Director of Eurotunnel NRS Holders Company Limited (United Kingdom).
Total Compensation: $ —
—
Total Compensation: $ —
Christian Lajoux has a degree (DEUG) in psychology, a bachelor degree (maitrise) in philosophy and a post-graduate degree (DESS) in personnel management from the Institut d'Administration des Entreprises (IAE Paris). He served in a variety of positions at Sandoz, including Division Director, before joining Sanofi Winthrop in 1993. He then served in various positions, including Director of Operations and Managing Director of Sanofi Winthrop France, before being appointed Senior Vice President France just prior to the merger with Synthelabo in 1999. He served in that position until being named as Senior Vice President Europe in January 2003, and then as Senior Vice President Pharmaceutical Operations France in August 2004. He was appointed as Chairman of Leem (Les entreprises du medicament) in July 2006.
Total Compensation: $ —
Gilles Lhernould has a diploma in pharmacy and a master's degree (DEA) in industrial pharmacy. He began his career as a manufacturing supervisor at Laboratoires Bruneau, and in 1983 joined one of Sanofi's subsidiaries where he managed production and later the factory. Mr. Lhernould then served in a variety of positions within the Sanofi Group, including Director of Human Resources - Pharmaceuticals for Sanofi Pharma and Director of Operational Human Resources for Sanofi. Following the merger with Synthelabo in 1999, he served as Vice President in charge of integration and then Vice President of Information Systems, before being named as Senior Vice President, Industrial Affairs in March 2001 and Senior Vice President Industrial Affairs of sanofi-aventis in August 2004.
Total Compensation: $ —
Hanspeter Spek graduated from business school in Germany. In 1974, he completed a management training program at Pfizer International, and then joined Pfizer RFA as a junior product manager. He served in various positions at Pfizer RFA, including as manager of the marketing division. Mr. Spek joined Sanofi Pharma GmbH, a German subsidiary of Sanofi, in 1985 as Marketing Director, and served in various positions in Germany and then at Sanofi in France, before being named Senior Vice President Europe following the merger with Synthelabo in 1999. He served as Executive Vice President, International Operations from October 2000, until January 2003, when he was named in charge of worldwide operations of Sanofi-Synthelabo. He was appointed to his present position in August 2004.
Total Compensation: $ —
Jean-Claude Armbruster has a diploma (DES) and a bachelor degree (maitrise) in private law, and a diploma (DES) in criminology. He also holds a barrister's practicing certificate (CAPA). He joined Sanofi's legal staff in 1980 and served in a variety of positions, including Director of Human Resources at Sanofi, before being named as Senior Vice President, Corporate Human Resources in October 2000 and reappointed to the same position in August 2004. He was appointed to his present position in October 2006. He was a member of the Executive Committee until December 31, 2006.
Total Compensation: $ —
Jean-Claude Leroy has a degree in business (DESCAF) from the Ecole Superieure de Commerce at Reims, France. He began his career at Elf Aquitaine in 1975 as an internal auditor, and worked in a variety of financial positions prior to joining Sanofi as the Financial Director of Bio Industries in 1985. Mr. Leroy served in a variety of positions at Sanofi, including Financial Director, and was appointed as Senior Vice President, Finance following the merger with Synthelabo in 1999. He was named as Senior Vice President, Strategy, Business Development and Information Systems in October 2000. He was appointed Senior Vice President and Chief Financial Officer of sanofi-aventis in August 2004, before being named Executive Vice President and Chief Financial Officer in April 2006. He was appointed to his present position in March 2007.
Total Compensation: $ —
Jean-Francois Dehecq, Chairman of the Board of Directors. Other directorships and appointments: Director of Air France, Agence Nationale de la Recherche and Veolia Environnement; Chairman of Association Nationale de la Recherche Technique; Chairman of the Board of Directors of ENSAM (Ecole Nationale Superieure d'Arts et Metiers); Member of Fondation Francaise pour la Recherche sur l'Epilepsie; Vice Chairman of EFPIA (European Federation of Pharmaceutical Industries and Associations); Member of IFPMA (International Federation of Pharmaceutical Manufacturers Associations); Governor to the Board of the American Hospital of Paris.
Total Compensation: $ —
Lindsay Owen-Jones, Chairman and Chief Executive Officer of L'Oreal. Chairman of Strategy Committee of L'Oreal. Director of Galderma Pharma S.A (Switzerland), Ferrari S.p.A (Italy). Chairman of L'Oreal USA Inc. and L'Oreal UK Ltd. Vice-Chairman of the Supervisory Board of L'Air Liquide
Total Compensation: $ —
Lord Douro, Chairman of Richemont Holdings UK Ltd. Director of La Compagnie Financiere Richemont AG (Switzerland), Pernod Ricard, GAM Worldwide (United Kingdom). Member of the Compensation Committee and the Appointments Committee of Pernod Ricard. Member of Appointments Committee of La Compagnie Financiere Richemont AG (Switzerland). Senior Advisor of Calyon (United Kingdom). Commissioner of English Heritage (United Kingdom).
Total Compensation: $ —
Marie-Helene Laimay has a degree in business from a French business school (Ecole Superieure de Commerce et d'Administration des Entreprises) and a DECS (an accounting qualification). She spent three years as an auditor with Ernst & Young before joining Sanofi in 1985. Mrs. Laimay served in a variety of financial positions, including Financial Director of Sanofi's beauty division and Deputy Financial Director of Sanofi-Synthelabo following the merger with Synthelabo in 1999. From November 2000 to May 2002, she served as Vice President, Internal Audit, and from May 2002 to August 2004 as Senior Vice President, Chief Financial Officer, before being appointed to her present position.
Total Compensation: $ —
—
Total Compensation: $ —
Timothy Rothwell holds a B.A. from Drew University (New Jersey) and a J.D. from Seton Hall University. He began his career in 1972 as a patent attorney at Sandoz Pharmaceuticals, where he worked in a variety of positions, including as Chief Operating Officer for U.S. Business, until he left Sandoz in 1989. From 1989 to 1991, Timothy Rothwell worked in marketing and sales at both Squibb Corporation and Burroughs Wellcome before returning to Sandoz in 1992 as Chief Executive Officer of Sandoz U.S. Pharmaceuticals, a post he held until 1995. From 1995 to 1998, Mr. Rothwell served in a variety of senior management positions at Rhone-Poulenc Rorer, including President of Global Pharmaceutical Operations. He joined Pharmacia in 1998 where he served in a variety of positions, including Executive Vice President and President of Global Prescription Business, before joining Sanofi-Synthelabo in May 2003. He served as Senior Vice President Pharmaceutical Operations, United States from August 2004 to January 31, 2007. He was a member of the Executive Committee until January 31, 2007. As of February 1, 2007, he was appointed Chairman of sanofi-aventis US Inc. and sanofi-aventis US LLC.
Total Compensation: $ —
—
Total Compensation: $ —
Robert Castaigne, Chief Financial Officer of Total. Chairman and Chief Executive Officer of Total Chimie and Total Nucleaire. Director of Elf Aquitaine, Hutchinson, Total Gestion Filiales, Omnium Insurance & Reinsurance Company Ltd (Bermuda), Alphega (Bermuda), Petrofina (Belgium), Total Upstream UK Ltd and Total Gabon.
Total Compensation: $ —
Thierry Desmarest, Chairman and Chief Executive Officer of Total and Elf Aquitaine. Member of the Supervisory Boards of Areva. Director of L'Air Liquide.
Total Compensation: $ —
Mrs. Claudie Haignere is a certified rheumatologist and holds a doctorate in science specialized in neurosciences. She participated in several spatial missions (Station MIR in 1996, International Space Station in 2001). She also served as Ministre Francais Delegue a la Recherche et aux Nouvelles Technologies (2002-2004) and as Ministre Francais Delegue aux Affaires Europeennes (2004-2005). Since November 2005, Mrs. Claudie Haignere has been an Advisor of the Director General of the European Space Agency (ESA).
Total Compensation: $ —
Philippe Luscan is a graduate in Biotechnology of the Ecole Polytechnique and the Ecole des Mines in Paris. He began his career in 1987 as a Production Manager at Danone. In 1990, he joined the Group as Director of the Sanofi Chimie plant at Sisteron, France, and subsequently served as Industrial Director of Sanofi in the United States and as Vice President Supply Chain. He was appointed to his present position in September 2006.
Total Compensation: $ —
Wayne Pisano holds a bachelor's degree in biology from St. John Fisher College, Rochester, New York, and an MBA from the University of Dayton, Ohio. Prior to sanofi pasteur he held various marketing and sales positions with Reed and Carnrick Pharmaceuticals and Sandoz/Novartis. He joined sanofi pasteur as Vice President, U.S. Marketing in May 1997 and then served as Senior Vice President of US Marketing & Sales, Executive Vice President of sanofi pasteur North America and Senior Vice President, Global Commercial Operations . He was appointed to his present position in August 2007.
Total Compensation: $ —
Jean-Philippe Santoni holds a doctorate in Medicine and a masters' degree in Human Biology. He began his career as a clinician specializing in hospital medicine and biology at various Academic Hospitals from the "Assistance Publique -Hopitaux de Paris" (APHP group). From 1985, he held various posts with responsibility for international clinical development and medical/regulatory affairs, first with Servier and subsequently with American Cyanamid/Lederle. In 1990, he joined Synthelabo as International Medical Director. Following the merger with Sanofi in 1999, he served successively as Associate Vice President Medical and Regulatory Affairs, Vice President International Clinical Operations and Vice President International Clinical Development, a position he retained after the merger with Aventis in 2004. He was appointed to his present position in January 2007.
Total Compensation: $ —
Mr. Uwe Bicker is a physician and holds a doctorate in chemistry. He is a Professor at the Medical Faculty of the Heidelberg University and a Doctor honoris causa at the Klausenburg University. He has been a member of the Board of Bertelsmann Stiftung (Foundation Bertelsmann) since January 2008.
Total Compensation: $ —
Mr. Patrick de la Chevardiere is a graduate of the Ecole Centrale de Paris. Since September 2003, he has served as Deputy Chief Financial Officer of Total.
Total Compensation: $ —
Mr. Gunter Thielen has a doctorate in physical chemistry and a degree in economics and industrial engineering. Since January 2008, he has served as Chairman of the Supervisory Board of Bertelsmann AG, Gutersloh and Chairman of the Executive Board of Bertelsmann Stiftung (Foundation Bertelsmann).
